ArticlePloS one2012
Tin oxide nanowires suppress herpes simplex virus-1 entry and cell-to-cell membrane fusion.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Review
- Mpox and Viral Co-Infections: A Narrative Review.Health science reports · 2025Article
- The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis.Clinical microbiology reviews · 2024Review
- Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.International journal of molecular sciences · 2023Review
- Antiviral activity of biosynthesized copper nanoparticle byIranian journal of microbiology · 2023Article
- Investigation of the Inhibition Activity of Aluminium Oxide Nanoparticles for Herpes Simplex Type 1.Archives of Razi Institute · 2023Article
- Masks for COVID-19.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Nanotechnology: A Potential Weapon to Fight against COVID-19.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2022Review
- Antiviral performance of graphene-based materials with emphasis on COVID-19: A review.Medicine in drug discovery · 2021Review
- Metal-Based Nanomaterials: Work as Drugs and Carriers against Viral Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Antiviral Nanomaterials for Designing Mixed Matrix Membranes.Membranes · 2021Review
- Progress and Perspective of Antiviral Protective Material.Advanced fiber materials · 2020Review
- Herpes Simplex Virus: The Hostile Guest That Takes Over Your Home.Frontiers in microbiology · 2020Review
- Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery.Science advances · 2019Article
- Multi-core-shell composite SnOEnvironmental science and pollution research international · 2019Article
- Metal-Based Nanoparticles for the Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2017Review
- Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.Nanomedicine : nanotechnology, biology, and medicine · 2017Review
- DNA-AuNP networks on cell membranes as a protective barrier to inhibit viral attachment, entry and budding.Biomaterials · 2016Article
- Cell entry mechanisms of HSV: what we have learned in recent years.Future virology · 2015Article
- Layer by Layer Ex-Situ Deposited Cobalt-Manganese Oxide as Composite Electrode Material for Electrochemical Capacitor.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The advent of nanotechnology has ushered in the use of modified nanoparticles as potential antiviral agents against diseases such as herpes simplex virus 1 and 2 (HSV-1) (HSV-2), human immunodeficiency virus (HIV), monkeypox virus, and hepatitis B virus. Here we describe the application of tin oxide (SnO(2)) nanowires as an effective treatment against HSV-1 infection. SnO(2) nanowires work as a carrier of negatively charged structures that compete with HSV-1 attachment to cell bound heparan sulfate (HS), therefore inhibiting entry and subsequent cell-to-cell spread. This promising new approach can be developed into a novel form of broad-spectrum antiviral therapy especially since HS has been shown to serve as a cellular co-receptor for a number of other viruses as well, including the respiratory syncytial virus, adeno-associated virus type 2, and human papilloma virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.